Estrella Immunopharma (ESLA) Financials: Revenue & Earnings
ESLA$0.86-0.08 -8.06%
$37.29M
Market Cap
—
P/E
—
Forward P/E
—
Score
Estrella Immunopharma (ESLA) Financials: Revenue & Earnings
ESLA price $0.86 -0.08 -8.06%
- Ticker
- ESLA
- Price
- $0.86
- Change
- -0.08 -8.06%
- Market cap ?
- $37.29M
- Beta ?
- 0.93
- Sector
- Healthcare
- Industry
- Biotechnology
Fair value
ESLA fair value Not meaningful. Price $0.86.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Not meaningful
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-12-02 | — | -0.08 | — | — |
| 2026-08-13 | -0.05 | -0.05 | — | — |
| 2026-05-13 | -0.05 | -0.08 | — | — |
| 2026-03-18 | -0.14 | -0.18 | — | — |
| 2025-11-12 | -0.13 | -0.19 | — | — |
| 2025-08-11 | -0.15 | -0.07 | — | — |
| 2025-05-14 | -0.06 | -0.11 | — | — |
| 2025-02-15 | -0.12 | -0.12 | — | — |
| 2024-11-14 | -0.09 | — | — | — |
| 2024-09-27 | -0.13 | — | — | — |
| 2024-05-14 | -0.01 | — | — | — |
| 2024-02-14 | -0.03 | — | — | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-08-25 | Liu Cheng | Buy | 100.00K | $0.81 | 81.50K |
| 2026-08-25 | Liu Cheng | Buy | 100.00K | $0.81 | 81.50K |
| 2026-08-18 | Xu Jiandong | Sell | 100.00K | $0.81 | 81.50K |
| 2026-08-18 | Xu Jiandong | Buy | 100.00K | $0.81 | 81.50K |
| 2025-10-07 | Xu Jiandong | Buy | 1.00K | $1.33 | 1.33K |
| 2025-09-22 | Xu Jiandong | Buy | 1.00K | $1.16 | 1.16K |
| 2025-09-22 | Jia Dengyao | Other | 0 | — | — |
| 2025-09-11 | Xu Jiandong | Buy | 100 | $1.04 | 104 |
| 2024-10-30 | Liu Cheng | Buy | 509.20K | $0.81 | 415.00K |
| 2024-10-30 | Liu Cheng | Buy | 490.80K | $0.81 | 400.00K |
| 2024-10-30 | Xu Jiandong | Buy | 509.20K | $0.81 | 415.00K |
| 2024-10-30 | Xu Jiandong | Buy | 490.80K | $0.81 | 400.00K |
| 2024-08-14 | Zhang Hong | Other | 0 | — | — |
| 2023-09-29 | Xu Jiandong | Sell | 0 | — | — |
| 2023-09-29 | Roberts Marsha | Other | 0 | — | — |
| 2023-09-29 | Xu Pei | Other | 0 | — | — |
| 2023-09-29 | Liu Cheng | Sell | 0 | — | — |
| 2023-09-29 | Wu Xuejun Janelle | Other | 0 | — | — |
| 2023-09-29 | Wu Fan | Other | 0 | — | — |
| 2023-09-29 | Eureka Therapeutics, Inc. | Sell | 0 | — | — |
| 2023-09-29 | Eureka Therapeutics, Inc. | Other | 0 | — | — |
| 2023-09-29 | Owl Creek Asset Management, L.P. | Sell | 255.00K | $10.86 | 2.77M |
| 2023-09-29 | TradeUP Acquisition Sponsor LLC | Other | 0 | — | — |
| 2023-09-29 | Long James | Other | 0 | — | — |
| 2023-09-29 | Jiang Tao | Other | 0 | — | — |
| 2023-09-29 | Wen Luqi | Other | 0 | — | — |
| 2023-09-29 | Li Jianwei | Other | 0 | — | — |
| 2023-09-29 | Twigg Weston | Other | 0 | — | — |
| 2023-09-29 | Yang Weiguang | Other | 0 | — | — |
| 2023-01-05 | Owl Creek Asset Management, L.P. | Other | 0 | — | — |
| 2022-03-04 | Li Jianwei | Buy | 141.97K | $314,700.00 | 44.68B |
| 2021-07-14 | Jiang Tao | Sell | 0 | — | — |
| 2021-07-14 | Twigg Weston | Sell | 0 | — | — |
| 2021-07-14 | Long James | Sell | 0 | — | — |
| 2021-07-14 | Yang Weiguang | Other | 0 | — | — |
| 2021-07-14 | TradeUP Acquisition Sponsor LLC | Sell | 0 | — | — |
| 2021-07-14 | Wen Luqi | Other | 0 | — | — |
| 2021-07-14 | Li Jianwei | Other | 0 | — | — |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 15, holders -1 vs prior quarter. Ownership 11.15%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 3.98M | -123.78K | -3.02% | 4.13M |
| VANGUARD CAPITAL MANAGEMENT LLC | 416.85K | 34.38K | +8.99% | 433.53K |
| GEODE CAPITAL MANAGEMENT, LLC | 141.32K | -16.16K | -10.26% | 146.97K |
| VANGUARD FIDUCIARY TRUST CO | 64.92K | 0 | 0.00% | 67.52K |
| BLACKROCK, INC. | 52.03K | 12.14K | +30.44% | 54.11K |
| STATE STREET CORP | 43.25K | 0 | 0.00% | 44.98K |
| RENAISSANCE TECHNOLOGIES LLC | 39.10K | -23.70K | -37.73% | 40.66K |
| NORTHERN TRUST CORP | 34.86K | 15.24K | +77.64% | 36.26K |
| US BANCORP \DE\ | 20.00K | 3.10K | +18.32% | 20.80K |
| TOWER RESEARCH CAPITAL LLC (TRC) | 3.31K | -1.55K | -31.92% | 3.44K |
| UBS GROUP AG | 1.72K | -13.36K | -88.59% | 1.79K |
| TORONTO DOMINION BANK | 1.09K | 0 | 0.00% | 1.13K |
| WOLVERINE ASSET MANAGEMENT LLC | 468 | 0 | 0.00% | 487 |
| BARCLAYS PLC | 126 | 126 | New | 131 |
| CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 2 | 2 | New | 2 |
| MORGAN STANLEY | 0 | -1 | -100.00% | 0 |
| ROYAL BANK OF CANADA | 0 | -6.60K | -100.00% | 0 |
| WELLS FARGO & COMPANY/MN | 0 | -264.39K | -100.00% | 0 |
Earnings and financials
Estrella Immunopharma, Inc. (ESLA) trades at $0.86, with a market cap of $37.29M and a trailing P/E of n/a. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Insights · Dividends · Forecast · Financials · Learn